Osteoporosis Newswire (Page 6)

Osteoporosis Newswire (Page 6)

Comprehensive Real-Time News Feed for Osteoporosis. (Page 6)

Results 101 - 120 of 1,431 in Osteoporosis

  1. Specific long-term therapy may not save older women from fracturesRead the original story

    Apr 6, 2017 | Newkerala.com

    Washington D.C. [USA], Jun 4 : Older women may want to rethink about getting a specific long-term therapy as according to a recent study, it may not prevent fractures. Osteoporosis is a disease that causes thinning of the bones, loss of bone density, and increasingly fragile bones.

    Comment?

  2. Study finds higher risk of fractures among older, long-term bisphosphonate usersRead the original story w/Photo

    Jun 2, 2017 | Medical News

    Osteoporosis is a disease that causes thinning of the bones, loss of bone density, and increasingly fragile bones. This puts people at higher risk for bone fractures.

    Comment?

  3. Mice headed to International Space Station to test osteoporosis drugRead the original story w/Photo

    Jun 2, 2017 | UPI

    While The Muppets sent pigs into space, researchers at the University of California, Los Angeles, are opting for rodents in order to test the protective effects of an experimental bone drug. Researchers at UCLA, will be sending 40 mice to the International Space Station to test an experimental drug based on the bone-building protein NELL-1.

    Comment?

  4. Bone loss is another hidden pathology caused by malaria infectionRead the original story w/Photo

    Jun 2, 2017 | PhysOrg Weblog

    ... deposition of new bone by osteoblasts and resorption of old bone by osteoclasts. Bone diseases, including osteoporosis and rheumatoid arthritis, are the result of increased ... Accumulating evidence suggests that rates of low bone mass are greater ...

    Comment?

  5. Mice headed for space to test bone-building drugRead the original story w/Photo

    Jun 2, 2017 | PhysOrg Weblog

    ... these three elements together to test an experimental drug that could one day result in a treatment for osteoporosis, which affects more than 200 million people worldwide. The drug could also potentially help those with bone damage or loss, a ...

    Comment?

  6. Osteoporosis rises as adults skip milkRead the original story w/Photo

    Jun 1, 2017 | Bangkok Post

    Adults should be better educated on the benefits of increased milk consumption as the dietary calcium intake in Asia remains low, the Food and Agriculture Organisation of the United Nations said on World Milk Day yesterday. While there has been plenty of advocacy to increase milk consumption among children in the Asia-Pacific region, osteoporosis remains a pressing concern among older people, said Vinod Ahuja, an FAO Policy Officer based in Bangkok.

    Comment?

  7. 3 Top Dividend Stocks in Generic DrugsRead the original story

    May 26, 2017 | Fox News

    ... of generics across the world, with its leading products including generic versions of antibiotic Augmentin, osteoporosis drug Aclasta, and hypothyroidism treamentSynthroid. In 2016, Novartis' retail generics business generated sales of $8.6 billion. ...

    Comment?

  8. Radius Health's Osteoporosis Drug Meets All Primary and Secondary Endpoints in Phase III TestRead the original story

    May 24, 2017 | BioSpace

    ACTIVExtend trial demonstrated sustained statistically significant fracture risk reduction through the 3.5 years of sequential therapy: TYMLOS followed by an antiresorptive Company to Host Top Line Results and Launch Update Webcast Today at 4:30 p.m. ET WALTHAM, Mass., May 24, 2017 -- Radius Health, Inc. a science-driven fully integrated biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, today announced positive top-line results from the completed 24 month ACTIVExtend trial, which met all of its primary and secondary endpoints.

    Comment?

  9. Taking bone density pillsRead the original story

    May 25, 2017 | The Western Producer

    Q: I am 60 years old and female and have some borderline osteoporosis and low minerals in my bones. My doctor has prescribed Alendronate, which I am supposed to take once a week, but it gives me heartburn and makes me feel ill for a couple of days.

    Comment?

  10. Radius Announces Positive Top-Line Results from Completed ACTIVExtend ...Read the original story

    May 24, 2017 | Information Technology

    ACTIVExtend trial demonstrated sustained statistically significant fracture risk reduction through the 3.5 years of sequential therapy: TYMLOS followed by an antiresorptivei 1 2 Company to Host Top Line Results and Launch Update Webcast Today at 4:30 p.m. ET WALTHAM, Mass., May 24, 2017 -- Radius Health, Inc. a science-driven fully integrated biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, today announced positive top-line results from the completed 24 month ACTIVExtend trial, which met all of its primary and secondary endpoints.

    Comment?

  11. Radius Announces Positive Top-Line Results from Completed ACTIVExtend ...Read the original story

    May 24, 2017 | Customer Interaction Solutions

    ACTIVExtend trial demonstrated sustained statistically significant fracture risk reduction through the 3.5 years of sequential therapy: TYMLOS followed by an antiresorptive Company to Host Top Line Results and Launch Update Webcast Today at 4:30 p.m. ET WALTHAM, Mass., May 24, 2017 -- Radius Health, Inc. a science-driven fully integrated biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, today announced positive top-line results from the completed 24 month ACTIVExtend trial, which met all of its primary and secondary endpoints.

    Comment?

  12. Puma Bio FDA Advisory Panel Live BlogRead the original story w/Photo

    May 24, 2017 | TheStreet.com

    ... bombshells in the FDA's neratinib review are a Monday win for Puma bulls, and the stock is soaring. Amgen's osteoporosis setback will likely be seen as providing a commercial boost to Radius Health, which secured U.S. approval in April for a ...

    Comment?

  13. Osteoporosis Prevention: 5-Point Plan to Stop Bone LossRead the original story w/Photo

    May 23, 2017 | News Max

    Osteoporosis and low bone mass, which puts folks at increased risk of this debilitating disease, affects a whopping 54 million people in the United States. Ten million actually have the condition while another 44 million have low bone density which puts them at greater risk.

    Comment?

  14. UK competition watchdog accuses Merck of obstructing biosimilarsRead the original story w/Photo

    May 23, 2017 | Reuters

    ... payments to insurers up in the air for 2017 and 2018. Amgen Inc and UCB SA no longer expect their experimental osteoporosis drug to win U.S. approval this year after a higher rate of serious heart-related side effects were observed in a late-stage ...

    Comment?

  15. Japan to target big increase in use of generic drugs: sourcesRead the original story w/Photo

    May 22, 2017 | Reuters

    ... payments to insurers up in the air for 2017 and 2018. Amgen Inc and UCB SA no longer expect their experimental osteoporosis drug to win U.S. approval this year after a higher rate of serious heart-related side effects were observed in a late-stage ...

    Comment?

  16. Amgen shares drop, Ford climbsRead the original story

    May 22, 2017 | The Standard

    Amgen and its partner UCB said women who took their experimental osteoporosis drug Evenity were more likely to have serious cardiovascular problems than patients who took Fosamax, an older drug. The companies said that was a new safety concern and they no longer expect the Food and Drug Administration to approve Evenity this year.

    Comment?

  17. Regeneron, Sanofi rheumatoid arthritis drug wins U.S. approvalRead the original story w/Photo

    May 22, 2017 | Reuters

    ... payments to insurers up in the air for 2017 and 2018. Amgen Inc and UCB SA no longer expect their experimental osteoporosis drug to win U.S. approval this year after a higher rate of serious heart-related side effects were observed in a late-stage ...

    Comment?

  18. Stocks bounce back as technology and defense companies climbRead the original story w/Photo

    May 22, 2017 | SouthCoastToday.com

    ... gained $2.91, or 1.6 percent, to $183.67. Amgen and its partner UCB said women who took their experimental osteoporosis drug Evenity were more likely to have serious cardiovascular problems than patients who took Fosamax, an older drug. The ...

    Comment?

  19. Amgen Can Shrug Off Its Bone-Drug RisksRead the original story w/Photo

    May 22, 2017 | Bloomberg

    ... Quartz and Business Insider. With promising trial results and an FDA approval seemingly near, Amgen Inc.'s osteoporosis drug Evenity was expected to contribute at least something to the company's top line this year.  But Amgen on ...

    Comment?

  20. Binge drinking less common among teens todayRead the original story w/Photo

    May 22, 2017 | Reuters

    ... individuals to develop problematic substance use." Amgen Inc and UCB SA no longer expect their experimental osteoporosis drug to win U.S. approval this year after a higher rate of serious heart-related side effects were observed in a late-stage ...

    Comment?